ORDER A TEST Log In Contact Us

NEWS

Press Releases

Media Coverage

Additional Partnerships

Filter By
For all media inquiries, please contact media@tempus.com
  • 08/28/2024

    Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, NY. Tempus Founder and CEO, Eric Lefkofsky, will speak...

  • 08/08/2024

    NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

    Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay has been published in npj Precision Oncology. Titled, “Detecting HLA loss of heterozygos...

  • 08/06/2024

    Tempus Reports Second Quarter 2024 Results

    CHICAGO, August 6, 2024 — Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024, and provided recent business highlights. Revenue increased 25% year-over-year to $166.0 million in the second quarter of 2024 Data licensing rev...

  • 08/01/2024

    Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

    New RNA-based algorithm is now available with the xR assay

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guid...

  • 07/30/2024

    Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease. The collaboration between Remix and Tempus began with the licensing of specific, de-identified da...

  • 07/17/2024

    Tempus to Report Second Quarter 2024 Financial Results on August 6

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the sa...

  • 07/16/2024

    Tempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests

    Available Today for Life Science Research Use Only Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based portfolio bein...

  • 07/10/2024

    Tempus Surpasses 500 Research Publications

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its diagnostic offerings, while also working with biopharma and academic collaborators to publish research s...

  • 07/08/2024

    American Medical Association Grants PLA Code to Tempus Algorithmic Test, PurISTSM

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. T...

  • 07/02/2024

    CMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test

    Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced Diagnostic Laboratory Test (ADLT) status for Tempus’ next-generation sequencing assay, xT CDx. xT CDx is the first Food and Drug Administration (FDA)-ap...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20